Journal article suggests heart risks with Pargluva diabetes drug

10/21/2005 | Wall Street Journal, The

Researchers who examined information from Bristol-Myers Squibb's clinical trials of its Pargluva diabetes drug recommended in the Journal of the American Medical Association the drug should undergo another trial to test it for heart safety. The researchers said the data show the drug could be linked to heart attacks, strokes and death. The FDA cited a need for such information in declining to approve the drug, despite a strong recommendation from an advisory panel. The drugmaker and Merck, the drug's co-marketer, said there are "many different and appropriate ways to analyze data."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
FDA/Device Technology Attorney
Quarles & Brady
Washington, DC
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Executive Medical Director
Aspirus Network Inc
Wausau, WI
Columbus, OH
Director, Membership
The Food and Drug Law Institute
Washington, DC